TY - JOUR T1 - The continued hunt for the elusive standard short regimen for treatment of multidrug-resistant tuberculosis JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00224-2020 VL - 55 IS - 3 SP - 2000224 AU - J. Peter Cegielski AU - Payam Nahid AU - Giovanni Sotgiu Y1 - 2020/03/01 UR - http://erj.ersjournals.com/content/55/3/2000224.abstract N2 - With three new and three recently repurposed drugs, treatment of multidrug-resistant tuberculosis (MDR-TB) is more hopeful today than at any time since it emerged in the 1980s and 1990s [1–3]. This optimism contrasts starkly with dismal global treatment success rates of 48–56% as reported by the World Health Organization (WHO) in its annual Global Tuberculosis Reports from 2014 to 2019 [4, 5].In low- and middle-income countries, treatment of highly selected MDR-TB patients with a standardised 9–12 month regimen leads to 80% or better successful treatment outcomes http://bit.ly/384SFpY ER -